APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biologic Medications for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Industry Research

Biologic Medications for Psoriasis Industry Research Report 2026

Report ID 173970670527 December 2025138 pages

Choose your research edition.

Industry ResearchBiologic Medications for Psoriasis Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologic Medications for Psoriasis Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Biologic Medications for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologic Medications for Psoriasis Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologic Medications for Psoriasis Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Biologic Medications for Psoriasis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Biologic Medications for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Biologic Medications for Psoriasis is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Biologic Medications for Psoriasis is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Biologic Medications for Psoriasis include AbbVie Biotechnology, Amgen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Biotech, Kyowa Kirin, LEO Pharma and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Biologic Medications for Psoriasis market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Biologic Medications for Psoriasis Market by Company

AbbVie Biotechnology

Amgen

Boehringer Ingelheim Pharmaceuticals

Bristol-Myers Squibb

Eli Lilly

Janssen Biotech

Kyowa Kirin

LEO Pharma

Novartis

Ortho Dermatologics

Pfizer

Samsung Bioepis

Tiefenbacher Pharmaceuticals

UCB

Dalian Yawei Pharmaceutical

Hanwha Chemical

China Medical System

Qilu Pharmaceutical

Biologic Medications for Psoriasis Segment by Type

Interleukin Inhibitors

Tyrosine Kinase Inhibitors

Phosphodiesterase Inhibitors

TNF-α Inhibitors

Other

Biologic Medications for Psoriasis Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

Biologic Medications for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Medications for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologic Medications for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Medications for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Biologic Medications for Psoriasis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Biologic Medications for Psoriasis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Biologic Medications for Psoriasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Biologic Medications for Psoriasis Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Biologic Medications for Psoriasis Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Biologic Medications for Psoriasis Sales Market Share by Manufacturers (2021-2026) Table 8. Global Biologic Medications for Psoriasis Revenue of Manufacturers (2021-2026) Table 9. Global Biologic Medications for Psoriasis Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Biologic Medications for Psoriasis Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Biologic Medications for Psoriasis Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Biologic Medications for Psoriasis, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Biologic Medications for Psoriasis, Product Type & Application Table 14. Global Biologic Medications for Psoriasis Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Biologic Medications for Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. AbbVie Biotechnology Company Information Table 19. AbbVie Biotechnology Business Overview Table 20. AbbVie Biotechnology Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio Table 22. AbbVie Biotechnology Recent Developments Table 23. Amgen Company Information Table 24. Amgen Business Overview Table 25. Amgen Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Amgen Biologic Medications for Psoriasis Product Portfolio Table 27. Amgen Recent Developments Table 28. Boehringer Ingelheim Pharmaceuticals Company Information Table 29. Boehringer Ingelheim Pharmaceuticals Business Overview Table 30. Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio Table 32. Boehringer Ingelheim Pharmaceuticals Recent Developments Table 33. Bristol-Myers Squibb Company Information Table 34. Bristol-Myers Squibb Business Overview Table 35. Bristol-Myers Squibb Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio Table 37. Bristol-Myers Squibb Recent Developments Table 38. Eli Lilly Company Information Table 39. Eli Lilly Business Overview Table 40. Eli Lilly Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Eli Lilly Biologic Medications for Psoriasis Product Portfolio Table 42. Eli Lilly Recent Developments Table 43. Janssen Biotech Company Information Table 44. Janssen Biotech Business Overview Table 45. Janssen Biotech Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Janssen Biotech Biologic Medications for Psoriasis Product Portfolio Table 47. Janssen Biotech Recent Developments Table 48. Kyowa Kirin Company Information Table 49. Kyowa Kirin Business Overview Table 50. Kyowa Kirin Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio Table 52. Kyowa Kirin Recent Developments Table 53. LEO Pharma Company Information Table 54. LEO Pharma Business Overview Table 55. LEO Pharma Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. LEO Pharma Biologic Medications for Psoriasis Product Portfolio Table 57. LEO Pharma Recent Developments Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Novartis Biologic Medications for Psoriasis Product Portfolio Table 62. Novartis Recent Developments Table 63. Ortho Dermatologics Company Information Table 64. Ortho Dermatologics Business Overview Table 65. Ortho Dermatologics Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio Table 67. Ortho Dermatologics Recent Developments Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Pfizer Biologic Medications for Psoriasis Product Portfolio Table 72. Pfizer Recent Developments Table 73. Samsung Bioepis Company Information Table 74. Samsung Bioepis Business Overview Table 75. Samsung Bioepis Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio Table 77. Samsung Bioepis Recent Developments Table 78. Tiefenbacher Pharmaceuticals Company Information Table 79. Tiefenbacher Pharmaceuticals Business Overview Table 80. Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio Table 82. Tiefenbacher Pharmaceuticals Recent Developments Table 83. UCB Company Information Table 84. UCB Business Overview Table 85. UCB Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. UCB Biologic Medications for Psoriasis Product Portfolio Table 87. UCB Recent Developments Table 88. Dalian Yawei Pharmaceutical Company Information Table 89. Dalian Yawei Pharmaceutical Business Overview Table 90. Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio Table 92. Dalian Yawei Pharmaceutical Recent Developments Table 93. Hanwha Chemical Company Information Table 94. Hanwha Chemical Business Overview Table 95. Hanwha Chemical Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio Table 97. Hanwha Chemical Recent Developments Table 98. China Medical System Company Information Table 99. China Medical System Business Overview Table 100. China Medical System Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. China Medical System Biologic Medications for Psoriasis Product Portfolio Table 102. China Medical System Recent Developments Table 103. Qilu Pharmaceutical Company Information Table 104. Qilu Pharmaceutical Business Overview Table 105. Qilu Pharmaceutical Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio Table 107. Qilu Pharmaceutical Recent Developments Table 108. Global Biologic Medications for Psoriasis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Biologic Medications for Psoriasis Sales by Region (2021-2026) & (K Units) Table 110. Global Biologic Medications for Psoriasis Sales Market Share by Region (2021-2026) Table 111. Global Biologic Medications for Psoriasis Sales by Region (2027-2032) & (K Units) Table 112. Global Biologic Medications for Psoriasis Sales Market Share by Region (2027-2032) Table 113. Global Biologic Medications for Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Biologic Medications for Psoriasis Revenue Market Share by Region (2021-2026) Table 115. Global Biologic Medications for Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Biologic Medications for Psoriasis Revenue Market Share by Region (2027-2032) Table 117. North America Biologic Medications for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 119. North America Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 120. North America Biologic Medications for Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Biologic Medications for Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Biologic Medications for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 124. Europe Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 125. Europe Biologic Medications for Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Biologic Medications for Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Biologic Medications for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 129. Asia Pacific Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 130. Asia Pacific Biologic Medications for Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Biologic Medications for Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Biologic Medications for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 134. South America Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 135. South America Biologic Medications for Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Biologic Medications for Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Biologic Medications for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 139. Middle East and Africa Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 140. Middle East and Africa Biologic Medications for Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Biologic Medications for Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Biologic Medications for Psoriasis Sales by Type (2021-2026) & (K Units) Table 143. Global Biologic Medications for Psoriasis Sales by Type (2027-2032) & (K Units) Table 144. Global Biologic Medications for Psoriasis Sales Market Share by Type (2021-2026) Table 145. Global Biologic Medications for Psoriasis Sales Market Share by Type (2027-2032) Table 146. Global Biologic Medications for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Biologic Medications for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Biologic Medications for Psoriasis Revenue Market Share by Type (2021-2026) Table 149. Global Biologic Medications for Psoriasis Revenue Market Share by Type (2027-2032) Table 150. Global Biologic Medications for Psoriasis Price by Type (2021-2026) & (US$/Unit) Table 151. Global Biologic Medications for Psoriasis Price by Type (2027-2032) & (US$/Unit) Table 152. Global Biologic Medications for Psoriasis Sales by Application (2021-2026) & (K Units) Table 153. Global Biologic Medications for Psoriasis Sales by Application (2027-2032) & (K Units) Table 154. Global Biologic Medications for Psoriasis Sales Market Share by Application (2021-2026) Table 155. Global Biologic Medications for Psoriasis Sales Market Share by Application (2027-2032) Table 156. Global Biologic Medications for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Biologic Medications for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Biologic Medications for Psoriasis Revenue Market Share by Application (2021-2026) Table 159. Global Biologic Medications for Psoriasis Revenue Market Share by Application (2027-2032) Table 160. Global Biologic Medications for Psoriasis Price by Application (2021-2026) & (US$/Unit) Table 161. Global Biologic Medications for Psoriasis Price by Application (2027-2032) & (US$/Unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Biologic Medications for Psoriasis Distributors List Table 165. Biologic Medications for Psoriasis Customers List Table 166. Biologic Medications for Psoriasis Industry Trends Table 167. Biologic Medications for Psoriasis Industry Drivers Table 168. Biologic Medications for Psoriasis Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Biologic Medications for Psoriasis Product Image Figure 5. Global Biologic Medications for Psoriasis Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Biologic Medications for Psoriasis Market Size (2021-2032) & (US$ Million) Figure 7. Global Biologic Medications for Psoriasis Sales (2021-2032) & (K Units) Figure 8. Global Biologic Medications for Psoriasis Average Price (US$/Unit) & (2021-2032) Figure 9. Interleukin Inhibitors Product Image Figure 10. Tyrosine Kinase Inhibitors Product Image Figure 11. Phosphodiesterase Inhibitors Product Image Figure 12. TNF-α Inhibitors Product Image Figure 13. Other Product Image Figure 14. Retail Pharmacies Product Image Figure 15. Hospital and Clinic Product Image Figure 16. Other Product Image Figure 17. Global Biologic Medications for Psoriasis Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Biologic Medications for Psoriasis, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Biologic Medications for Psoriasis Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Biologic Medications for Psoriasis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Biologic Medications for Psoriasis Sales by Region in 2025 Figure 23. Global Biologic Medications for Psoriasis Revenue by Region in 2025 Figure 24. North America Biologic Medications for Psoriasis Market Size by Country in 2025 Figure 25. North America Biologic Medications for Psoriasis Sales Market Share by Country (2021-2032) Figure 26. North America Biologic Medications for Psoriasis Revenue Market Share by Country (2021-2032) Figure 27. United States Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Biologic Medications for Psoriasis Market Size by Country in 2025 Figure 31. Europe Biologic Medications for Psoriasis Sales Market Share by Country (2021-2032) Figure 32. Europe Biologic Medications for Psoriasis Revenue Market Share by Country (2021-2032) Figure 33. Germany Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Biologic Medications for Psoriasis Market Size by Country in 2025 Figure 44. Asia Pacific Biologic Medications for Psoriasis Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Biologic Medications for Psoriasis Revenue Market Share by Country (2021-2032) Figure 46. China Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Biologic Medications for Psoriasis Market Size by Country in 2025 Figure 55. South America Biologic Medications for Psoriasis Sales Market Share by Country (2021-2032) Figure 56. South America Biologic Medications for Psoriasis Revenue Market Share by Country (2021-2032) Figure 57. Brazil Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Biologic Medications for Psoriasis Market Size by Country in 2025 Figure 61. Middle East and Africa Biologic Medications for Psoriasis Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Biologic Medications for Psoriasis Revenue Market Share by Country (2021-2032) Figure 63. Egypt Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Biologic Medications for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Biologic Medications for Psoriasis Sales Market Share by Type (2021-2032) Figure 69. Global Biologic Medications for Psoriasis Revenue Market Share by Type (2021-2032) Figure 70. Global Biologic Medications for Psoriasis Price (US$/Unit) by Type (2021-2032) Figure 71. Global Biologic Medications for Psoriasis Sales Market Share by Application (2021-2032) Figure 72. Global Biologic Medications for Psoriasis Revenue Market Share by Application (2021-2032) Figure 73. Global Biologic Medications for Psoriasis Price (US$/Unit) by Application (2021-2032) Figure 74. Biologic Medications for Psoriasis Value Chain Figure 75. Biologic Medications for Psoriasis Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Biologic Medications for Psoriasis Industry Opportunities and Challenges

Scope & coverage.

Types
  • Interleukin Inhibitors
  • Tyrosine Kinase Inhibitors
  • Phosphodiesterase Inhibitors
  • TNF-α Inhibitors
  • Other
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • AbbVie Biotechnology
  • Amgen
  • Boehringer Ingelheim Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly
  • Janssen Biotech
  • Kyowa Kirin
  • LEO Pharma
  • Novartis
  • Ortho Dermatologics
  • Pfizer
  • Samsung Bioepis
  • Tiefenbacher Pharmaceuticals
  • UCB
  • Dalian Yawei Pharmaceutical
  • Hanwha Chemical
  • China Medical System
  • Qilu Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Biologic Medications for Psoriasis Market Size (2021-2032)
  4. 2.2.2 Global Biologic Medications for Psoriasis Sales (2021-2032)
  5. 2.2.3 Global Biologic Medications for Psoriasis Market Average Price (2021-2032)
  6. 2.3 Biologic Medications for Psoriasis by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Interleukin Inhibitors
  9. 2.3.3 Tyrosine Kinase Inhibitors
  10. 2.3.4 Phosphodiesterase Inhibitors
  11. 2.3.5 TNF-α Inhibitors
  12. 2.3.6 Other
  13. 2.4 Biologic Medications for Psoriasis by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Retail Pharmacies
  16. 2.4.3 Hospital and Clinic
  17. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Biologic Medications for Psoriasis Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Biologic Medications for Psoriasis Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Biologic Medications for Psoriasis Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Biologic Medications for Psoriasis Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Biologic Medications for Psoriasis Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Biologic Medications for Psoriasis, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Biologic Medications for Psoriasis, Product Type & Application
  8. 3.8 Global Manufacturers of Biologic Medications for Psoriasis, Established Date
  9. 3.9 Global Biologic Medications for Psoriasis Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 AbbVie Biotechnology
  2. 4.1.1 AbbVie Biotechnology Company Information
  3. 4.1.2 AbbVie Biotechnology Business Overview
  4. 4.1.3 AbbVie Biotechnology Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio
  6. 4.1.5 AbbVie Biotechnology Recent Developments
  7. 4.2 Amgen
  8. 4.2.1 Amgen Company Information
  9. 4.2.2 Amgen Business Overview
  10. 4.2.3 Amgen Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Amgen Biologic Medications for Psoriasis Product Portfolio
  12. 4.2.5 Amgen Recent Developments
  13. 4.3 Boehringer Ingelheim Pharmaceuticals
  14. 4.3.1 Boehringer Ingelheim Pharmaceuticals Company Information
  15. 4.3.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  16. 4.3.3 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
  18. 4.3.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  19. 4.4 Bristol-Myers Squibb
  20. 4.4.1 Bristol-Myers Squibb Company Information
  21. 4.4.2 Bristol-Myers Squibb Business Overview
  22. 4.4.3 Bristol-Myers Squibb Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio
  24. 4.4.5 Bristol-Myers Squibb Recent Developments
  25. 4.5 Eli Lilly
  26. 4.5.1 Eli Lilly Company Information
  27. 4.5.2 Eli Lilly Business Overview
  28. 4.5.3 Eli Lilly Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly Biologic Medications for Psoriasis Product Portfolio
  30. 4.5.5 Eli Lilly Recent Developments
  31. 4.6 Janssen Biotech
  32. 4.6.1 Janssen Biotech Company Information
  33. 4.6.2 Janssen Biotech Business Overview
  34. 4.6.3 Janssen Biotech Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Janssen Biotech Biologic Medications for Psoriasis Product Portfolio
  36. 4.6.5 Janssen Biotech Recent Developments
  37. 4.7 Kyowa Kirin
  38. 4.7.1 Kyowa Kirin Company Information
  39. 4.7.2 Kyowa Kirin Business Overview
  40. 4.7.3 Kyowa Kirin Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio
  42. 4.7.5 Kyowa Kirin Recent Developments
  43. 4.8 LEO Pharma
  44. 4.8.1 LEO Pharma Company Information
  45. 4.8.2 LEO Pharma Business Overview
  46. 4.8.3 LEO Pharma Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 LEO Pharma Biologic Medications for Psoriasis Product Portfolio
  48. 4.8.5 LEO Pharma Recent Developments
  49. 4.9 Novartis
  50. 4.9.1 Novartis Company Information
  51. 4.9.2 Novartis Business Overview
  52. 4.9.3 Novartis Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Novartis Biologic Medications for Psoriasis Product Portfolio
  54. 4.9.5 Novartis Recent Developments
  55. 4.10 Ortho Dermatologics
  56. 4.10.1 Ortho Dermatologics Company Information
  57. 4.10.2 Ortho Dermatologics Business Overview
  58. 4.10.3 Ortho Dermatologics Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio
  60. 4.10.5 Ortho Dermatologics Recent Developments
  61. 4.11 Pfizer
  62. 4.11.1 Pfizer Company Information
  63. 4.11.2 Pfizer Business Overview
  64. 4.11.3 Pfizer Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Pfizer Biologic Medications for Psoriasis Product Portfolio
  66. 4.11.5 Pfizer Recent Developments
  67. 4.12 Samsung Bioepis
  68. 4.12.1 Samsung Bioepis Company Information
  69. 4.12.2 Samsung Bioepis Business Overview
  70. 4.12.3 Samsung Bioepis Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio
  72. 4.12.5 Samsung Bioepis Recent Developments
  73. 4.13 Tiefenbacher Pharmaceuticals
  74. 4.13.1 Tiefenbacher Pharmaceuticals Company Information
  75. 4.13.2 Tiefenbacher Pharmaceuticals Business Overview
  76. 4.13.3 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
  78. 4.13.5 Tiefenbacher Pharmaceuticals Recent Developments
  79. 4.14 UCB
  80. 4.14.1 UCB Company Information
  81. 4.14.2 UCB Business Overview
  82. 4.14.3 UCB Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 UCB Biologic Medications for Psoriasis Product Portfolio
  84. 4.14.5 UCB Recent Developments
  85. 4.15 Dalian Yawei Pharmaceutical
  86. 4.15.1 Dalian Yawei Pharmaceutical Company Information
  87. 4.15.2 Dalian Yawei Pharmaceutical Business Overview
  88. 4.15.3 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
  90. 4.15.5 Dalian Yawei Pharmaceutical Recent Developments
  91. 4.16 Hanwha Chemical
  92. 4.16.1 Hanwha Chemical Company Information
  93. 4.16.2 Hanwha Chemical Business Overview
  94. 4.16.3 Hanwha Chemical Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio
  96. 4.16.5 Hanwha Chemical Recent Developments
  97. 4.17 China Medical System
  98. 4.17.1 China Medical System Company Information
  99. 4.17.2 China Medical System Business Overview
  100. 4.17.3 China Medical System Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 China Medical System Biologic Medications for Psoriasis Product Portfolio
  102. 4.17.5 China Medical System Recent Developments
  103. 4.18 Qilu Pharmaceutical
  104. 4.18.1 Qilu Pharmaceutical Company Information
  105. 4.18.2 Qilu Pharmaceutical Business Overview
  106. 4.18.3 Qilu Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
  108. 4.18.5 Qilu Pharmaceutical Recent Developments
5 Global Biologic Medications for Psoriasis Market Scenario by Region
  1. 5.1 Global Biologic Medications for Psoriasis Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Biologic Medications for Psoriasis Sales by Region: 2021-2032
  3. 5.2.1 Global Biologic Medications for Psoriasis Sales by Region: 2021-2026
  4. 5.2.2 Global Biologic Medications for Psoriasis Sales by Region: 2027-2032
  5. 5.3 Global Biologic Medications for Psoriasis Revenue by Region: 2021-2032
  6. 5.3.1 Global Biologic Medications for Psoriasis Revenue by Region: 2021-2026
  7. 5.3.2 Global Biologic Medications for Psoriasis Revenue by Region: 2027-2032
  8. 5.4 North America Biologic Medications for Psoriasis Market Facts & Figures by Country
  9. 5.4.1 North America Biologic Medications for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Biologic Medications for Psoriasis Sales by Country (2021-2032)
  11. 5.4.3 North America Biologic Medications for Psoriasis Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Biologic Medications for Psoriasis Market Facts & Figures by Country
  16. 5.5.1 Europe Biologic Medications for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Biologic Medications for Psoriasis Sales by Country (2021-2032)
  18. 5.5.3 Europe Biologic Medications for Psoriasis Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Biologic Medications for Psoriasis Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Biologic Medications for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Biologic Medications for Psoriasis Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Biologic Medications for Psoriasis Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Biologic Medications for Psoriasis Market Facts & Figures by Country
  41. 5.7.1 South America Biologic Medications for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Biologic Medications for Psoriasis Sales by Country (2021-2032)
  43. 5.7.3 South America Biologic Medications for Psoriasis Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Biologic Medications for Psoriasis Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Biologic Medications for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Biologic Medications for Psoriasis Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Biologic Medications for Psoriasis Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Biologic Medications for Psoriasis Sales by Type (2021-2032)
  2. 6.1.1 Global Biologic Medications for Psoriasis Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Biologic Medications for Psoriasis Sales Market Share by Type (2021-2032)
  4. 6.2 Global Biologic Medications for Psoriasis Revenue by Type (2021-2032)
  5. 6.2.1 Global Biologic Medications for Psoriasis Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Biologic Medications for Psoriasis Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Biologic Medications for Psoriasis Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Biologic Medications for Psoriasis Sales by Application (2021-2032)
  2. 7.1.1 Global Biologic Medications for Psoriasis Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Biologic Medications for Psoriasis Sales Market Share by Application (2021-2032)
  4. 7.2 Global Biologic Medications for Psoriasis Revenue by Application (2021-2032)
  5. 7.2.1 Global Biologic Medications for Psoriasis Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Biologic Medications for Psoriasis Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Biologic Medications for Psoriasis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Biologic Medications for Psoriasis Value Chain Analysis
  2. 8.1.1 Biologic Medications for Psoriasis Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Biologic Medications for Psoriasis Production Mode & Process
  5. 8.2 Biologic Medications for Psoriasis Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Biologic Medications for Psoriasis Distributors
  8. 8.2.3 Biologic Medications for Psoriasis Customers
9 Global Biologic Medications for Psoriasis Analyzing Market Dynamics
  1. 9.1 Biologic Medications for Psoriasis Industry Trends
  2. 9.2 Biologic Medications for Psoriasis Industry Drivers
  3. 9.3 Biologic Medications for Psoriasis Industry Opportunities and Challenges
  4. 9.4 Biologic Medications for Psoriasis Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst